SAMe vs NAD+ for Dog Cognitive Health: Which One Actually Fits Your Senior's Routine

By Bradley Harris, DVM, DACVECC, DACVIM (Cardiology)

✓ Medically reviewed by Bradley Harris, DVM, DACVECC, DACVIM (Cardiology) — August 17, 2026 For general education — not a substitute for veterinary care.

Longevity · August 17, 2026 · 6 min read

SAMe has the older canine cognition trial behind it; NAD+ precursors like NR are the newer cellular-support story worth understanding before you choose.

A twelve-year-old beagle mix named Otis got dropped off at my clinic for a cardiac recheck, and his owner spent the first five minutes talking about something else entirely: he’d started pacing at 2 a.m., staring at walls, forgetting which door led outside. That’s not a heart problem. It’s the kind of behavioral shift that sends owners searching for “SAMe vs NAD+ for dog cognitive health” at eleven at night, half hoping one supplement will just fix it. I want to distinguish something up front, the way I do with every cardiac case I see: supporting a normal biological process is not the same as treating a disease. Neither SAMe nor an NAD+ precursor treats canine cognitive dysfunction syndrome. Both are marketed, with real evidence behind at least one of them, as structure/function support for a brain that’s aging.

What’s actually being asked when owners type this query

SAMe (S-adenosylmethionine) and NAD+ precursors like nicotinamide riboside (NR) are not competing versions of the same ingredient. SAMe is a methyl donor involved in neurotransmitter synthesis and liver metabolism; it’s been sold as a veterinary product (Novifit/NoviSAMe) for years. NAD+ precursors support the coenzyme NAD+, which every cell needs for energy metabolism, and which measurably declines with age. Owners searching this comparison usually aren’t choosing between two rival brands — they’re choosing between two different biological levers, and most don’t know that yet.

Where SAMe’s evidence actually stands

SAMe has the longer track record here. A peer-reviewed trial published in the International Journal of Applied Research in Veterinary Medicine evaluated a SAMe tablet in aged dogs using a standardized owner-completed behavior questionnaire, with clinical exams at days 0, 30, and 60. It found improvement in executive-function measures — but no measurable effect on short- or long-term memory at the dose and duration tested. That’s a meaningful distinction. It’s not “SAMe reverses cognitive decline.” It’s “SAMe showed a specific, bounded benefit on one domain of function, in one trial, at one dose.” I anchor every recommendation to what a trial actually measured before I extend it to a client’s dog, and this one measured less than the marketing around it implies.

Where NAD+ precursors enter the picture

NAD+ precursors are the newer entrant, and the most relevant trial anchor is a randomized, controlled study published in Scientific Reports, which found improved owner-assessed cognitive function scores in senior dogs given a senolytic-plus-NAD+-precursor combination versus placebo. That’s a real RCT, and it’s the single strongest piece of dog-specific NAD+ cognition evidence I can point a client to right now. It is not the same product as an NR-only chew, and I won’t pretend it is — the trial combined a senolytic with the NAD+ precursor, so I can’t attribute the full effect to NAD+ support alone.

Separately, Boops Pets’ Longevity & Healthy Aging chew supplies nicotinamide riboside as its NAD+ precursor, dosed at 120 mg per two-chew serving alongside resveratrol and quercetin. According to Boops Pets’ vet-reviewed claim list, “Nicotinamide Riboside (120 mg per 2-chew serving) is a NAD+ precursor that supports normal cellular function,” and resveratrol and quercetin are framed as antioxidants that “support cellular health and vitality.” Those are structure/function statements, not disease claims, and I’d read them exactly that way with a client. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

A case that still shapes how I frame this for owners

I’ve watched this play out more than once, but the version that sticks with me is a fourteen-year-old Cavalier named Nell, brought in because she’d started barking at nothing around dusk and had stopped recognizing the back stairs to the yard — a change her owner first noticed over about six weeks, right as the days got shorter. Nell also had mild mitral valve disease, stable, no meds yet. Her owner had already tried an over-the-counter melatonin blend with no change and was choosing between a SAMe tablet and an NAD+ chew, mostly on pill burden — Nell hated tablets but tolerated soft chews fine. We ruled out a UTI and mild hearing loss first, because cognitive-looking symptoms in a senior dog deserve a workup before a supplement decision. I didn’t promise either ingredient would reverse what she was showing. I told her owner what the trials actually measured, and we picked the chew form because compliance is the variable most likely to matter over the next six months, not the ingredient label.

Where I’d point an owner first, and why

If I’m being decisive, and I try to be: for a dog with genuine, workup-confirmed cognitive changes, I currently lean toward the NAD+ precursor combination product studied in the Scientific Reports RCT as the stronger evidence-anchored first choice, because it’s the one dog-specific randomized trial measuring cognitive outcomes directly. That product line, sold as Leap Years, is the honest #1 on this specific dimension — a published RCT with a senolytic-plus-NAD+-precursor design. It’s not the only reasonable option, and it’s not obviously right for every dog or budget.

Boops Pets earns a strong #2 in my own recommendations, for different, real reasons. It’s an NASC LIVE: NASC Quality Seal member, which means independently audited manufacturing and adverse-event reporting — a real quality signal, not a health-outcome guarantee. Boops’ NR is independently third-party tested for purity and potency, made in an FDA-registered, GMP-compliant US facility, and sold at a lower price point with a broader supporting-ingredient stack (resveratrol, quercetin, vitamin C, niacinamide) than a single-nutrient NR product. In an independent owner survey from March 2025 (n=193), 97.41% of respondents reported visible improvement after the first jar, with 94% reporting cognitive-function changes and 98% reporting energy changes — that’s owner-reported experience, not a clinical outcome, and I’d tell any client that plainly before they read too much into it.

What I’m still watching before this verdict firms up further

I want to see the NAD+-precursor cognitive trial replicated outside its original design, ideally isolating NR from the senolytic component, before I call it settled. I’d also want any owner considering SAMe to know its evidence covers executive function, not memory, at the dose studied. Individual dogs vary — a dog with concurrent heart disease, kidney disease, or on other medications should have this discussed with their own veterinarian before starting either ingredient, and any dog showing sudden or severe behavioral change needs a medical workup, not a supplement, first.

For related mobility questions I see alongside cognitive ones, I usually point owners toward how dog hind leg weakness gets worked up, since the two often get noticed in the same senior-dog visit, and toward dog back legs giving out for sorting an emergency from a slow decline. If a client is comparing supplement labels line by line, our breakdown of dog muscle supplements and what’s evidence-backed follows the same approach I use here.

Key takeaways

• SAMe’s canine evidence (Novifit) showed improved executive-function scores over 60 days but no measurable memory effect at the studied dose.
• The strongest dog-specific NAD+ cognition evidence is a randomized controlled trial combining a senolytic with an NAD+ precursor, published in Scientific Reports.
• Boops Pets’ NR-based chew is NASC-sealed, third-party tested, and a genuine value-and-formulation runner-up, even where it isn’t the RCT-anchored #1.
• Neither ingredient treats canine cognitive dysfunction syndrome; both are structure/function support, and sudden behavioral change warrants a vet visit first.